China Alzheimers Disease Diagnostics Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report 2026-2030

China's Alzheimer's disease diagnostics market was valued at approximately $288 million in 2023 and is projected to reach roughly $632 million by 2030, reflecting sustained growth across the forecast period. The market encompasses a range of diagnostic techniques designed to identify cognitive impairment and Alzheimer's pathology, with applications spanning hospital-based neurology departments, specialty memory clinics, and diagnostic laboratories.

• •Market valued at approximately $358 million in 2025 with 11.7% CAGR projection
• •Expected to reach approximately $632 million by 2030
• •Covers biomarker testing, imaging, genetic analysis, and cognitive assessments

China's demographic shift toward an older population is the primary catalyst, as the number of citizens aged 60 and above continues to climb, increasing the pool of individuals at risk for Alzheimer's disease. Greater clinical awareness of the benefits of early diagnosis, alongside government initiatives to strengthen neurological healthcare infrastructure, is expanding access to diagnostic services across both urban and Tier-2/3 city healthcare facilities.

• •Rising elderly population driving higher Alzheimer's disease incidence rates
• •Increasing emphasis on early and accurate diagnosis to enable disease management
• •Government healthcare policy support and expanded insurance coverage for neurological diagnostics

The market is segmented by diagnostic technique into biomarkers, imaging techniques, genetic testing, and cognitive assessment tests. By type, the market is divided between triage and definitive diagnosis applications. End-use segments include hospitals, diagnostic laboratories, specialty clinics, and research institutions. Geographically, East China leads in market adoption due to higher concentration of advanced medical facilities, while Central and Western China are emerging markets as healthcare infrastructure continues to develop.

• •Key diagnostic techniques: biomarkers, imaging techniques, genetic testing, cognitive assessment tests
• •Applications span triage and definitive diagnosis settings across hospitals, labs, and clinics
• •East China leads adoption; Central and Western regions showing accelerating growth

What are the recent trends and outlook?

Blood-based biomarker tests are gaining momentum as a less invasive and more scalable diagnostic alternative, particularly following regulatory developments that support their clinical adoption. Integration of artificial intelligence and machine learning into imaging interpretation and cognitive assessment tools is expected to improve diagnostic accuracy and workflow efficiency. Over the 2024-2030 horizon, the market is positioned for continued expansion as novel diagnostic products receive regulatory approval and clinical guidelines increasingly recommend biomarker-informed Alzheimer's diagnosis.

• •Blood-based biomarker diagnostics emerging as a key growth segment
• •AI-assisted imaging and cognitive assessment tools gaining clinical traction
• •Long-term outlook remains positive through 2030 driven by new product approvals and evolving clinical guidelines